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How to manage the transplant question in myeloﬁbrosis
K Ballen
Allogeneic stem cell transplantation remains the only curative therapy for myeloﬁbrosis. Despite advances in transplant, the
morbidity and the mortality of the procedure necessitate careful patient selection. In this manuscript, we describe the new
prognostic scoring system to help select appropriate patients for transplant and less aggressive therapies. We explore the
advances in non-transplant therapy, such as with investigational agents. We review the blossoming literature on results of
myeloablative, reduced intensity and alternative donor transplantation. Finally, we make recommendations for which patients
are most likely to beneﬁt from transplantation.
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DEFINITIONS OF MYELOFIBROSIS
Myeloﬁbrosis is now categorized based on the World Health
Organization criteria as a myeloproliferative neoplasm. Myelo-
ﬁbrosis can be either primary or secondary, developing in
patients with polycythemia vera or essential thrombocythemia.
1
The median age is in the seventh decade and clinical features
include anemia, splenomegaly and bone marrow ﬁbrosis. About
70% of patients are positive for the Janus2 kinase (JAK2 kinase)
mutation.
2 Patients must fulﬁll all the three major criteria
(megakaryocyte proliferation, no evidence of other myeloid
neoplasm, and JAK2/V617F or other clonal marker, or no reactive
marrow ﬁbrosis) and two minor criteria (leukoerythroblastosis,
increased serum lactate dehydrogenase, anemia, palpable spleno-
megaly) to have primary myeloﬁbrosis.
3
RISK STRATIFICATION
Several prognostic systems have been developed over the last
20 years to help determine which patients might beneﬁt from
aggressive transplantation treatment. The older scoring system,
such as the Lille or Dupriez, and the Cervantes score, focused
primarily on blood counts as the major prognostic factors.
4
A newer prognostic system is the International Prognostic Scoring
System (IPSS), which includes age 465, hemoglobin level
o10, white blood count 425 10
9/l, circulating blasts X1% and
presence of constitutional symptoms.
5 The IPSS was
further modiﬁed to the dynamic IPSS (DIPSS) for use at any time
during the course of the disease, and then to the DIPSS Plus, which
also incorporates the need for red blood cell transfusions, platelet
count o100 10
9/l and unfavorable karyotype (Table 1).
6
PROGNOSIS
Newer prognostic models have incorporated the DIPSS Plus
model. Low-risk disease is deﬁned as the presence of no adverse
factors, and has a median survival of 15 years.
6 Intermediate-1 risk
is the presence of one risk factor and has a median survival of
7 years. Patients with intermediate-2 disease have two or
three risk factors and a median survival of 2.9 years. Finally,
high-risk patients have four or more adverse factors with a median
survival of only 1.3 years. Thus, these newer prognostic models
can aid in selecting the appropriate higher risk patients for
transplantation. Recently, an analysis of 884 patients, which
included 38% DIPSS Plus patients, reported features associated
with a greater than 80% 2-year mortality. These poor prognostic
features included monosomal karyotype, inv (3)/i(17q) abnormal-
ities, or any two of the following factors: peripheral blast
percentage 49%, white blood count X40 10
9/l or other
unfavorable karyotype.
7 Thus, these modern predictive scores
allow selection of patients who are likely to do poorly with
conventional treatment.
CHOICE OF TREATMENT
Although allogeneic hematopoietic stem cell transplantation
(HCT) remains the only known curative therapy for myeloﬁbrosis,
other treatment options must be considered, especially for
patients with lower risk disease. These options include obser-
vation, erythroid-stimulating agents, hydroxyurea, prednisone,
thalidomide or lenalidomide.
8,9 Response rates, including
improvement in blood counts and splenomegaly, vary but are
about 20%.
10 Low-dose radiation treatments or splenectomy can
also be helpful for painful splenomegaly.
11 These treatments may
be helpful for palliation of symptoms, but the responses are of
short duration, usually less than 1 year.





Age 465 years 1 1
Constitutional symptoms 1 1
Hemoglobin o100g/l 2 1
White blood count 425 10
9/l 1 1
Circulating blasts 41% 1 1
Platelet count o100 10
9/ l --- 1
Red blood cell transfusion-dependent - - - 1
Unfavorable karyotype - - - 1
Abbreviation: DIPSS, Dynamic International Prognostic Scoring System.
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Investigational options for the treatment of myeloﬁbrosis have
blossomed with the discovery of JAK2 kinase inhibitors. The JAK2
inhibitors tested in clinical trial include INCB018424, TG101348
and CEP-701.
12 The majority of patients had improvement in
constitutional symptoms, and 44% had improvement in spleen
size, with major side effects being thrombocytopenia and a
cytokine rebound reaction.
12 Other drugs under investigation
include pomalidomide and the histone deacetylase inhibitors.
13
The impact of these investigational agents on the long-term
management of myeloﬁbrosis is uncertain.
ALLOGENEIC STEM CELL TRANSPLANTATION
Myeloablative transplant
Allogeneic transplantation is the only known curative treatment
for myeloﬁbrosis. Several studies have shown survival rates of
40--60% after allogeneic stem cell transplantation (Table 2). The
ﬁrst transplants for myeloﬁbrosis used myeloablative conditioning,
usually total body radiation or busulfan-based treatment.
Guardiola et al.
14 reported on 55 patients with a median age of
42 years and showed a 5-year overall survival of 47%. Anemia was
a predictive factor for poor survival.
The largest study, reported by Ballen et al.
15 from the Center for
International Blood and Marrow Transplant Research (CIBMTR),
analyzed 289 patients with primary myeloﬁbrosis. Patients were
transplanted between 1989 and 2002 at 118 centers, with a variety
of conditioning regimens. Patient and disease characteristics were
very heterogeneous, as typical for registry studies. A total of 162
patients received a human leukocyte antigen (HLA)-matched
sibling transplant, 101 received a matched unrelated donor (MUD)
transplant and 26 received a graft from a non-HLA-matched
related donor. The majority of patients received bone marrow as
the stem cell source, and 83% received an ablative regimen, likely
reﬂecting the time period of the study. The 100-day transplant-
related mortality was 18% for the HLA-matched sibling patients
and 33% for the MUD patients. Graft failure rate was 9% for the
HLA-matched sibling patients and 20% for the MUD patients.
Splenomegaly did not impact the graft failure rate. Graft versus
host disease (GVHD) grades II--IV occurred in 43% of the sibling
patients and 40% of the MUD patients. The overall survival at 5
years was 37% for the sibling patients and 30% for the MUD
recipients. Disease-free survival at 5 years was 33% for recipients
of an HLA-identical sibling allograft and 27% for recipients of a
MUD transplant. Thus, about one out of three patients can be
cured of their disease after allogeneic transplant. Positive
predictors for survival in this study included an HLA-identical
sibling donor, performance status X90% and no peripheral blood
blasts.
15 Patients who had a poor Karnofsky score, peripheral
blood blasts and an unrelated donor had 15% 3-year probability of
survival.
Other reports of allogeneic transplant have conﬁrmed the
ﬁndings of the CIBMTR study. The Italian group analyzed
100 patients from 26 centers; 48% received a myeloablative
conditioning regimen.
16 The risk of graft failure was 13%, and the
1-year transplant-related mortality was 35%. The 5-year overall
and disease-free survival rates were 31% and 28%, respectively.
Positive predictors for survival included an HLA-matched sibling
donor, transplantation after 1995 and a short interval between
diagnosis and transplantation.
The French group reported similar results. A total of 147
patients with primary or secondary myeloﬁbrosis received an
allogeneic stem cell transplant, 31% with a myeloablative
regimen.
17 Sixty percent of patients received a transplant from
an HLA-identical sibling donor. Forty-three percent of patients had
acute GVHD, grades II--IV. The 4-year overall survival was 39%,
progression-free survival 32% and the non-relapse mortality was
39%. In a multivariate analysis, neither the Lille nor IPSS score
predicted survival. Positive predictors for survival included
splenectomy, female gender and an HLA-identical sibling donor.
Other studies have conﬁrmed these results. The Seattle group
reported on 104 patients with myeloﬁbrosis, either primary or
after polycythemia vera or essential thrombocythemia.
18 The
survival at 7 years was 61%. Use of a targeted busulfan-based
chemotherapy regimen, younger age and a lower comorbidity
score predicted for better survival. Investigators, including Mittal
et al.
19, Ditschokowski et al.
20, Deeg et al.
21, Kerbauy et al.
22 and
Daly et al.
23 have all reported 3-year probabilities of overall
survival of 37--58% in small series.
REDUCED-INTENSITY CONDITIONING
Because of the advanced age of many patients with myeloﬁbrosis
and hematological malignancies, and the high transplant-related
mortality with traditional myeloablative conditioning, the trans-
plant community has pioneered reduced-intensity conditioning
(RIC). The RIC regimens use chemotherapy, often ﬂudarabine-
based, which is more immunosuppressive than myelosuppres-
sive.
24- -26 Early RIC studies for myeloﬁbrosis included the work of
Devine et al.
27 and Rondelli et al.
28. Table 3 outlines the larger
studies for myeloﬁbrosis. Kroger et al.
29 treated 103 patients with
primary myeloﬁbrosis or myeloﬁbrosis post-polycythemia vera or
essential thrombocythemia. Patients received a busulfan- and
ﬂudarabine-based conditioning regimen. A total of 98% of the
patients engrafted, and acute GVHD grades II--IV occurred in 27%
of the patients. The incidence of relapse at 3 years was 22%, and
patients with a low Lille score had a lower incidence of relapse,
14% versus 34%, suggesting patients transplanted earlier in the
course of disease fared better. The 5-year event-free survival was
51% and as expected, younger patients and those with a matched
donor did better. These results are impressive and mimic the
survival seen with a myeloablative preparative regimen.
The Swedish group compared results from 17 patients under-
going myeloablative with 10 patients undergoing reduced
intensity transplant for myeloﬁbrosis.
30 Transplant-related mortal-
ity was lower in the reduced intensity arm, 10% versus 30%. With a
median follow-up of 55 months, 90% of reduced intensity patients
and 55% of the myeloablative patients are alive. However, the
Table 2. Allogeneic stem cell transplantation for myeloﬁbrosis
Author N Median age (years) 1-year TRM, % 5-year overall survival, % 5-year progression free-survival, %
Ballen et al.
15 289 47 27 (sibling), 43 (unrelated) 37 (sibling), 30 (unrelated) 33 (sibling), 27 (unrelated)
Patriarca et al.
16 100 49 35 31 28
Robin et al.
17 147 53 29 (4 years) 39 (4 years) 32 (4 years)
Kerbauy et al.
22 104 47 27 61 (7 years) -- -
Deeg et al.
21 56 43 35 58 -- -
Abbreviation: TRM, transplant-related mortality.
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of improved survival.
The CIBMTR study, reported by Ballen et al.
15 and described
above, included 60 patients who received reduced intensity or
non-myeloablative regimens. Transplant-related mortality was
15%, less than for the myeloablative patients, and disease-free
survival was comparable at 39%. Snyder et al.
31 using tacrolimus
and sirolimus for GVHD prophylaxis, reported a low incidence
(10%) of acute GVHD grades III--IV and 93% survival. Stewart
et al.
32 treated 27 patients with a myeloablative and 24 patients
with a reduced intensity regimen. There was no difference in non-
relapse mortality, overall survival or progression-free survival
between the myeloablative and reduced intensity groups. With
the use of RIC regimens, patients in their 60’s and 70’s have been
transplanted successfully.
33 Predictive factors for survival are
difﬁcult to ascertain in the large registry studies that combine
both myeloablative and RIC recipients. The RIC regimens have
been instrumental in expanding transplant eligibility; these
regimens reduce the transplant-related mortality compared with
high-intensity regimens, but without randomized studies, the
exact improvement in survival is difﬁcult to determine.
ALTERNATIVE DONOR TRANSPLANT
Only 30% of patients have a matched sibling donor and it is often
difﬁcult for African Americans and other minorities to ﬁnd MUDs.
Alternative stem cell graft sources for these patients include
umbilical cord blood, a mismatched unrelated donor, or a
mismatched family member (haploidentical) transplant. These
graft sources have never been compared in a randomized fashion,
and the optimal graft source for patients without a fully matched
related donor or MUD is uncertain.
34 Umbilical cord blood
transplantation is a useful alternative stem cell source for patients
without matched donors.
35 Because of the delayed engraftment
routinely seen after cord blood transplant, transplant physicians
may have been reluctant to extend cord blood transplantation to
patients with myeloﬁbrosis. The recent report of Takagi et al.
36
suggest that successful engraftment can be achieved after
reduced-intensity umbilical cord blood transplantation for myelo-
ﬁbrosis. Fourteen patients classiﬁed as myeloﬁbrosis, including
several that had transformed to acute myelogeneous leukemia,
underwent cord blood transplant with an RIC regimen. In all, 13
patients engrafted, and the overall survival was 29% at 4 years.
PREDICTORS FOR SURVIVAL
Selection of the appropriate patients for transplant and the
appropriate timing of transplant have been difﬁcult, given the
early risk associated with transplant, even a reduced intensity
transplant. Predictive factors studied have included age, graft
source, performance status, comorbidity score, splenomegaly,
Dupriez score or IPSS score. The CIBMTR study reported by Ballen
et al.
15 found that an HLA-identical sibling donor, performance
status X90% and no peripheral blood blasts predicted for better
survival. Recently, Bacigalupo et al.
37 have formulated a predictive
score for survival. Forty-six patients underwent a reduced inten-
sity transplant for primary myeloﬁbrosis with a thiotepa-based
regimen, either thiotepa and cyclophosphamide, or thiotepa,
cyclophosphamide and melphalan. In a multivariate analysis,
independent factors for poor survival were 420 red blood
cell transfusions, spleen size 422cm and an alternative donor.
Two or more risk factors were considered high risk, and these
high-risk patients had a 5-year survival of 8%, compared with 77%
for the low-risk patients with 0 or 1 risk factor. These results
suggest that certain high-risk patients may not beneﬁt from
allogeneic stem cell transplant. The predictive score maintained
its predictive value even when correcting for patient age, Dupriez,
or IPSS score.
Scott et al.
38 presented a preliminary analysis of predictive
factors for survival after allogeneic transplantation for myelo-
ﬁbrosis. The authors retrospectively studied 169 recipients
of allogeneic HCT in Seattle. The International Working Group
score, based on age, constitutional symptoms, anemia, leuko-
cytosis and circulating peripheral blasts, was highly predictive
for survival after HCT. At 1 year, survival was 40% in the high-risk
group and 80% in the low-risk group.
Splenomegaly and splenectomy
The appropriate management of the spleen pre-HCT remains
controversial. Ciurea et al.
39 showed prolonged neutrophil and
platelet recovery in patients with massive splenomegaly, but no
effect on survival. Preliminary data from the CIBMTR in a broader
population found that splenectomy facilitates engraftment, but
had no effect on transplant-related mortality.
40 Recently, post-
transplant splenectomy has been studied as a way to manage
delayed engraftment in patients with splenomegaly and myelo-
ﬁbrosis.
41
Markers of minimal residual disease
The role of JAK2 V617F status after transplant is controversial.
A study of 162 patients treated with RIC showed a reduced
survival in patients with the JAK2 wild type.
42 Patients who cleared
the JAK2 mutation 6 months after transplant had a lower risk
of relapse (5% versus 35%, P¼0.03). The reappearance of the
JAK2 gene mutation after transplant was associated with the
presence of mixed chimerism and relapse; thus, JAK2 mutation
serves as a marker of minimal residual disease.
43 The JAK2
kinase inhibitor ruxolitinib has recently been approved by the
United States Food and Drug Association and is commercially
available. The role of the JAK2 kinase inhibitors as part of a
transplantation strategy is unclear; these drugs might be helpful
for disease reduction pre-HCT or as maintenance therapy
post-HCT.
Treatment failure
The options for patients that relapse after HCT are limited.
Stewart et al.
32 showed a trend toward a higher rate of relapse in
Table 3. Reduced-intensity allogeneic stem cell transplantation for myeloﬁbrosis
Author N Median age (years) 1-year TRM, % 5-year overall survival, % 5-year progression-free survival, %
Kroger et al.
29 103 53 16 67 51
Merrup et al.
30 27 51 10 (RIC), 30 (ablative) 90 (RIC), 55 (ablative) - - -
Ballen et al.
15 60 47 (myeloablative and RIC) 15 -- - 39
Bacigalupo et al.
37 46 51 24 45 43
Alchalby et al.
42 162 57 22 62 46
Stewart et al.
32 51 54 32 (RIC), 41 (ablative; 3 years) 31 (RIC), 44 (ablative) 24 (RIC), 44 (ablative)
Abbreviations: RIC, reduced-intensity conditioning; TRM, transplant-related mortality.
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with patients who received myeloablative conditioning. Donor
lymphocyte infusion has been utilized for post-HCT relapse,
but it is not clear if there is a strong graft versus myeloﬁbrosis
effect.
32
CHOOSING BETWEEN TRANSPLANT AND NON-TRANSPLANT
THERAPY
Allogeneic transplant remains the only curative therapy for
myeloﬁbrosis, but the transplant-related mortality remains high,
at 15--30%, and there can be signiﬁcant morbidity for patients
with chronic GVHD. Thus, the selection of patients for transplant is
crucial. Some centers will transplant only those patients whose
median survival is less than 5 years without transplant, such as
those patients with intermediate-2 and high-risk disease.
44
Another approach would be to exclude patients with high-risk
features of splenomegaly 422cm, 420 transfusions and alter-
native donor as deﬁned by Bacigalupo et al.
37; these patients have
less than a 10% survival after HCT.
For low-risk patients, a more aggressive approach is to monitor
these patients and to perform transplant early in the disease if
there are any signs of progression, such as anemia, increased
lactate dehydrogenase or constitutional symptoms.
45
How to manage the transplant question in myeloﬁbrosis
At Massachusetts General Hospital, we perform allogeneic
transplants up to age 75. In general, patients over age 60 years
or with signiﬁcant comorbid disease will receive a reduced
intensity regimen, usually busulfan and ﬂudarabine. Younger
patients receive a myeloablative regimen with busulfan and
cyclophosphamide. Patients without a matched sibling donor
proceed to unrelated donor search. If an HLA 10/10 allele-matched
donor is identiﬁed, patients will receive an unrelated transplant.
Patients without matched related donor or fully MUD receive
double cord blood transplant at our center.
35 Patients must have a
performance status of 0, 1, 2 and adequate organ function to
proceed to transplant. An algorithm for transplantation is shown
in Figure 1.
As many patients with myeloﬁbrosis enjoy prolonged survival,
we select those patients whose survival is likely to be less than 5
years with conventional therapy. Patients with monosomal
karyotype have a median survival of 6 months and should be
transplanted promptly.
46
Patient with low-risk disease by the DIPSS criteria have a
median survival of 15 years and should not be considered for
transplant, given the morbidity and mortality of allogeneic
transplant.
10 Patients with intermediate-1 disease have a
median survival of 6 years; these patients are considered for
transplant and HLA typing performed. However, these patients’
symptoms can often be managed by hydroxyurea or low-dose
splenic radiation, and it is reasonable to try these measures
ﬁrst before proceeding to transplant. However, most patients
with intermediate-1 disease will die of myeloﬁbrosis or its
complications, and should be considered as potential transplant
candidates.
Patients with intermediate-2 have a median survival of 2.9 years,
and patients with high-risk disease have a median survival of 1.3
years. These patients are considered for immediate transplant as
soon as a suitable donor is identiﬁed. Patients who have
transformed to acute leukemia receive induction chemotherapy
before transplantation. Patients with massive splenomegaly may
undergo low-dose splenic radiation before transplant.
Patients who are likely to have o10% long-term survival after
transplant are excluded from transplant. These patients may have
the risk factors mentioned, including massively enlarged spleen
and a signiﬁcant transfusion requirement. Patients with poor
performance status and signiﬁcant comorbid conditions may not
be transplant candidates.
CONCLUSION
Treatment for myeloﬁbrosis has evolved with a better under-
standing of the prognostic factors for survival. Investigational
agents such as pomalidomide are currently in clinical trial, and a
JAK2 kinase inhibitor is now approved for use in the United States.
Allogeneic transplant remains the only known curative therapy for
this disease. The advent of RIC has extended the upper age limit of
HCT into the 70’s. Alternative donor transplantation, including
umbilical cord blood transplantation, has provided a larger
number of patients, particularly minority patients, with the option
for transplant. Over the next 5 years, reduction of transplant-
related mortality and optimal patient selection will ensure
continued progress in this ﬁeld.
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